Abstract library

335 results for "malignant carcinoids".
#640 Chomogranin A, NSE, and 5-Hydroxyindolacetic Acid Measurements in Malignant Carcinoids
Introduction: GEP-NETs are a heterogeneous group of cancers more common in the small intestine which are usually asymptomatic. In patients with malignant carcinoids, a number of tumor markers (TMs) have been considered enclosing urinary 5-hydroxyindolacetic acid (5-HIAA), chromogranin A (CgA), and neuron-specific enolase (NSE) serum levels measurements. Unfortunately, the sensitivity of each TM largely depends on disease extent and the presence of functioning tumors, and thus their usefulness is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Professor Franco Lumachi
#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids
Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Reidar Fossmark
#3006 Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma
Introduction: Mature cystic teratoma (MCT) is the most common type of germ cell tumor in the ovary. A malignant tumor that arises in a pre-existing mature teratoma is called teratoma with malignant transformation (TMT).
Conference: 17th Annual ENETS Conference (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia
#654 Identification of Signaling Pathways Involved in Lung Carcinoid Progression Using Gene Expression Profiling
Introduction: Lung carcinoids are well-differentiated neuroendocrine tumors (NETs) usually associated with a favorable prognosis. Mechanisms underlying progression are poorly understood.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MSc Dorian Swarts
#434 Treatment, Survival and Prognostic Markers in Patients with Thymic Carcinoids: A Clinicopathologic Study of 28 Cases
Introduction: Thymic carcinoids are uncommon but malignant tumors, usually associated with a poor prognosis. The number of cases reported is limited to a few hundred and there are few prognostic factors available.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Joakim Crona
#2029 Prognostic Factors of Pulmonary Carcinoid Tumors
Introduction: Pulmonary carcinoids (PC) are rare malignant neoplasms that account for approximately 1% of all lung cancers. PCs are classified by histological criteria as either typical (TC) or atypical (AC). Histological subtype is the most studied prognostic factor.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MSc Tiina Vesterinen
#318 The SEER as a Prophet: Epidemiological Analysis as a Harbinger of Evolving Priorities in Gastroenteropancreatic Neuroendocrine Neoplasia
Introduction: Previous epidemiology analysis of tumor registries established that gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) were both more prevalent, and more malignant, than previously recognized.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Mark Kidd
#3020 Outcomes Following Surgical Management of Pulmonary Carcinoids – A Tertiary Center Experience
Introduction: Pulmonary carcinoids are a rare type of malignant lung tumour. Surgery forms the mainstay of management when operable. However, there is paucity of data on conservative management and effective follow-up strategies.
Conference: 17th Annual ENETS Conference (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr Md Deloar Hoshen
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#1353 A Case Series of 27 Primary Ovarian Neuroendocrine Tumors
Introduction: Primary neuroendocrine tumors of the ovary are rare and often found incidentally.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Weinstein Yahel
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team